These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 19576490)

  • 1. [Different botulinum toxins and their specifications].
    Beylot C
    Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S77-85. PubMed ID: 19576490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of botulinum toxin: differences between type A preparations.
    Rosales RL; Bigalke H; Dressler D
    Eur J Neurol; 2006 Feb; 13 Suppl 1():2-10. PubMed ID: 16417591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type B (Myobloc).
    Baumann L; Black L
    Dermatol Surg; 2003 May; 29(5):496-500; discussion 500. PubMed ID: 12752517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
    Frevert J
    Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
    Vergilis-Kalner IJ
    J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin: examining duration of effect in facial aesthetic applications.
    Flynn TC
    Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
    Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes.
    Glogau RG
    Clin J Pain; 2002; 18(6 Suppl):S191-7. PubMed ID: 12569968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin (Botox, Dysport, and Myobloc): pharmacology 101.
    Wynn RL
    Gen Dent; 2011; 59(2):88-90. PubMed ID: 21903516
    [No Abstract]   [Full Text] [Related]  

  • 12. [Introduction. Botulinum toxin].
    Beylot C; Gassia V
    Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S53-4. PubMed ID: 19576485
    [No Abstract]   [Full Text] [Related]  

  • 13. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
    Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
    Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of botulinum neurotoxin type A for cosmetic applications.
    Carruthers J; Carruthers A
    J Cosmet Laser Ther; 2007 Sep; 9(3):186-92. PubMed ID: 17763029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin products overview.
    Carruthers A; Carruthers J
    Skin Therapy Lett; 2008; 13(6):1-4. PubMed ID: 18806905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary: Botulinum toxin in clinical medicine: part II.
    Benedetto AV
    Clin Dermatol; 2004; 22(1):1-2. PubMed ID: 15158537
    [No Abstract]   [Full Text] [Related]  

  • 17. [Long-term effects of botulinum toxin treatment].
    Krystkowiak P
    Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S86-8. PubMed ID: 19576491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the use of botulinum neurotoxins in facial esthetics.
    Flynn TC
    J Cosmet Dermatol; 2012 Mar; 11(1):42-50. PubMed ID: 22360334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of Botulinum Toxins for Aesthetic Uses.
    Gart MS; Gutowski KA
    Clin Plast Surg; 2016 Jul; 43(3):459-71. PubMed ID: 27363760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
    Simonetta Moreau M; Cauhepe C; Magues JP; Senard JM
    Br J Dermatol; 2003 Nov; 149(5):1041-5. PubMed ID: 14632812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.